Atara Secures FDA Resubmission Path for Tabelecleucel BLA, Preserves Review Timeline
ATRA•Atara Biotherapeutics said it will resubmit its Biologics License Application for tabelecleucel after receiving an FDA complete response letter, preserving its regulatory review timeline. The company confirmed it will provide additional manufacturing and clinical data to address FDA feedback and maintain its planned PDUFA target in early 2027.
1. Regulatory Resubmission Plan
Atara Biotherapeutics outlined its path to resubmit the BLA for tabelecleucel following FDA feedback on manufacturing and clinical data. The company plans to compile additional documentation on CMC processes and trial endpoints to uphold its projected review timeline and PDUFA target in early 2027.
